COVID-19 & Cancer

COVID-19 & Cancer

Early in 2020, we watched with growing alarm as early warnings of the virulence of SARS-CoV-2 started pouring in from Wuhan, and later, from Lombardy. At The Cancer Letter, we quickly decided to chart a course for intensive coverage of the pandemic as it reached our shores—oncologists are well-poised to take the lead in shaping research on COVID-19, and exposure mitigation strategies for high-risk patients. This coverage is collected here.
COVID-19 and the cancer patient: A call to action for balancing cancer care and viral risk
COVID-19 & CancerFreeGuest Editorial

COVID-19 and the cancer patient: A call to action for balancing cancer care and viral risk

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.As COVID-19 has now officially been declared a source of the pandemic, with increasing incidence across the nation, it is without question that the needs of patients with particular vulnerabilities should garner particular attention.
By Karen E. Knudsen and Roy A. Jensen
What to expect: Oncology’s response to coronavirus in Italy
Conversation with The Cancer LetterCOVID-19 & CancerFree

What to expect: Oncology’s response to coronavirus in Italy
"It's like being in a war"

To get a sense of how COVID-19 will affect oncology in the U.S., The Cancer Letter called Giuseppe Curigliano, associate professor of Medical Oncology at University of Milano and the head of the Division of Early Drug Development at European Institute of Oncology, Italy, who is based in the Lombardy region—the epicenter of the outbreak.
By Alexandria Carolan